NKTR - חוב כולל להון Nektar Corp

Nektar Therapeutics (NKTR) relies on patent protection and partnerships to generate royalties, although it is currently depleting reserves due to a lack of profitability. On the GURU.Markets platform, the d/e ratio (total debt to equity) visualizes the credit load, where the 0.14 mark characterizes this parameter. Diversification into immuno-oncology and inflammatory processes via an innovative platform minimizes biotechnological risks.

Nektar Therapeutics (NKTR) is accelerating the development of immuno-oncology drugs by leveraging AI and robotics to automate bioscreening. The debt_total_eq_co metric measures the proportion of borrowed funds relative to equity, determining the business's financial autonomy. The value 0.14 demonstrates the company's current degree of dependence on external borrowing. A low ratio minimizes risks associated with costly R&D developments. The trend in the debt-to-equity ratio confirms the balance sheet's resilience to market shocks.